IMUNON INC. - COMMON

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

25 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

07 Nov 2024 10:00:00 By Nasdaq GlobeNewswire

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

07 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

31 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

30 Oct 2024 09:05:00 By Nasdaq GlobeNewswire

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

07 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09 Sep 2024 16:06:00 By Nasdaq GlobeNewswire

IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON to Host R&D Day on September 18th

28 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

14 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

07 Aug 2024 17:04:00 By Nasdaq GlobeNewswire

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

29 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

24 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

05 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

15 May 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

13 May 2024 09:00:00 By Nasdaq GlobeNewswire

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

13 May 2024 08:00:01 By Nasdaq GlobeNewswire

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

08 May 2024 08:00:00 By Nasdaq GlobeNewswire